Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study

Journal of Diabetes Investigation

Volumn 2, Issue 5, 2011, Pages 391-398

  Shihara, Nobuyuki ^a   Kitaoka, Masafumi ^a,b   Inagaki, Nobuya ^a,d   Kadowaki, Takashi ^a,c   Koumoto, Seisuke ^a   Satoh, Jo ^a,e   Terauchi, Yasuo ^a,f   Nunoi, Kiyohide ^a,g   Yamada, Yuichiro ^a,h   Sakamaki, Hiroyuki ⁱ   Seino, Yutaka ^a,j  

^a Japan Association for Diabetes Education and Care   (Japan)

^b Showa General Hospital   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g ST MARY S HOSPITAL   (Japan)

^h AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ MEIJO UNIVERSITY   (Japan)

^j KANSAI ELECTRIC POWER CO   (Japan)

more..

Author keywords

Glimepiride; Pioglitazone; Type 2 diabetes mellitus

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; JAPANESE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80054003529     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00115.x     Document Type: Article

References (23)

1. National Institute of Health and Nutrition. Outline for the results of the National Health and Nutrition Survey Japan, 2007. Available at: [accessed on 2 August 2010].
2. Kanatsuka A, Kawai K, Hirao K, et al. Research on antihyperglycemic therapies in patients with type 2 diabetes mellitus in Japan (I): drug therapies and actual drug use. J Jpn Diabetes Soc 2006; 49: 409-415 (Japanese).
3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
4. Toyota T, Satoh J, Fukao A, et al. Clinical evaluation of glimepiride (HOE490) in non-insulin-dependent diabetes mellitus - a double-blind placebo-controlled study/phase III additional study. J Clin Ther Med 1997; 13: 157-158 (Japanese).
5. Draeger KE, Wernicke-Panten K, Lomp H-J, et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28: 419-425.
6. Dormandy JA, Charbonnel B, Eckland DJA, et al. on behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
8. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
9. Kawamori R, Kadowaki T, Onji M, et al. Hepatic safety profile and glycaemia control of pioglitazone in more than 20, 000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007; 76: 229-235.
10. Loke YK, Singh S, Furnberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
11. Tan M, Johns D, González Gálvez G, et al on behalf of the GLAD Study Group. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004; 26: 680-693.
12. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531.
13. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22: 751-759.
14. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.
15. Nissen SE, Nichols SJ, Wolski K, et al for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
16. Yamanouchi T, Sakai T, Igarashi K, et al. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med 2005; 22: 980-985.
17. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
18. Araki T, Emoto M, Konishi T, et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism 2009; 58: 143-148.
19. Xu D-Y, Zhao S-P, Huang Q-X, et al. Effects of glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 88: 71-75.
20. Kaneko T, Baba S, Toyota T. Clinical evaluation of an insulin-resistance improving agent, AD-4833, in patients with non-insulin dependent diabetes mellitus (NIDDM) on diet therapy alone. A placebo controlled double blind clinical study. Jpn J Clin Exp Med 1997; 74: 1515-1539 (Japanese).
21. Shakuto S, Oshima K, Tsuchiya E. Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2005; 182: 209-217.
22. Schaalan M, El-Abhar HS, Barakat M, et al. Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. J Diabetes Complications 2009; 23: 199-208.
23. Scholz GH, Schneider K, Knirsch W, et al. Efficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort study. Clin Drug Invest 2001; 21: 597-604.